165 related articles for article (PubMed ID: 30940449)
1. SENP2 suppresses NF-κB activation and sensitizes breast cancer cells to doxorubicin.
Gao X; Wu Y; Qiao L; Feng X
Eur J Pharmacol; 2019 Jul; 854():179-186. PubMed ID: 30940449
[TBL] [Abstract][Full Text] [Related]
2. NF-κB induction of the SUMO protease SENP2: A negative feedback loop to attenuate cell survival response to genotoxic stress.
Lee MH; Mabb AM; Gill GB; Yeh ET; Miyamoto S
Mol Cell; 2011 Jul; 43(2):180-91. PubMed ID: 21777808
[TBL] [Abstract][Full Text] [Related]
3. Silencing of SENP2 in Multiple Myeloma Induces Bortezomib Resistance by Activating NF-κB Through the Modulation of IκBα Sumoylation.
Xie H; Gu Y; Wang W; Wang X; Ye X; Xin C; Lu M; Reddy BA; Shu P
Sci Rep; 2020 Jan; 10(1):766. PubMed ID: 31964975
[TBL] [Abstract][Full Text] [Related]
4. Cucurbitacin D induces cell cycle arrest and apoptosis by inhibiting STAT3 and NF-κB signaling in doxorubicin-resistant human breast carcinoma (MCF7/ADR) cells.
Ku JM; Kim SR; Hong SH; Choi HS; Seo HS; Shin YC; Ko SG
Mol Cell Biochem; 2015 Nov; 409(1-2):33-43. PubMed ID: 26169986
[TBL] [Abstract][Full Text] [Related]
5. Shenmai injection suppresses multidrug resistance in MCF-7/ADR cells through the MAPK/NF-κB signalling pathway.
Yang L; Zhang C; Chen J; Zhang S; Pan G; Xin Y; Lin L; You Z
Pharm Biol; 2020 Dec; 58(1):276-285. PubMed ID: 32251615
[No Abstract] [Full Text] [Related]
6. MicroRNA-132 and microRNA-212 mediate doxorubicin resistance by down-regulating the PTEN-AKT/NF-κB signaling pathway in breast cancer.
Xie M; Fu Z; Cao J; Liu Y; Wu J; Li Q; Chen Y
Biomed Pharmacother; 2018 Jun; 102():286-294. PubMed ID: 29567542
[TBL] [Abstract][Full Text] [Related]
7. Nuclear factor-κB signaling inhibitors revert multidrug-resistance in breast cancer cells.
Abdin SM; Tolba MF; Zaher DM; Omar HA
Chem Biol Interact; 2021 May; 340():109450. PubMed ID: 33775688
[TBL] [Abstract][Full Text] [Related]
8. Ginkgolic acids inhibit migration in breast cancer cells by inhibition of NEMO sumoylation and NF-κB activity.
Hamdoun S; Efferth T
Oncotarget; 2017 May; 8(21):35103-35115. PubMed ID: 28402272
[TBL] [Abstract][Full Text] [Related]
9. Key role of nuclear factor-κB in the cellular pharmacokinetics of adriamycin in MCF-7/Adr cells: the potential mechanism for synergy with 20(S)-ginsenoside Rh2.
Zhang J; Lu M; Zhou F; Sun H; Hao G; Wu X; Wang G
Drug Metab Dispos; 2012 Oct; 40(10):1900-8. PubMed ID: 22745335
[TBL] [Abstract][Full Text] [Related]
10. Oestrogen treatment enhances the sensitivity of hormone-resistant breast cancer cells to doxorubicin.
Scherbakov AM; Lobanova YS; Andreeva OE; Shatskaya VA; Krasil'nikov MA
Biosci Rep; 2011 Apr; 31(2):137-43. PubMed ID: 20662767
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumor compound RY10-4 suppresses multidrug resistance in MCF-7/ADR cells by inhibiting PI3K/Akt/NF-κB signaling.
Yang X; Ding Y; Xiao M; Liu X; Ruan J; Xue P
Chem Biol Interact; 2017 Dec; 278():22-31. PubMed ID: 28987325
[TBL] [Abstract][Full Text] [Related]
12. Sinapine reverses multi-drug resistance in MCF-7/dox cancer cells by downregulating FGFR4/FRS2α-ERK1/2 pathway-mediated NF-κB activation.
Guo Y; Ding Y; Zhang T; An H
Phytomedicine; 2016 Mar; 23(3):267-73. PubMed ID: 26969380
[TBL] [Abstract][Full Text] [Related]
13. Doxorubicin induces drug resistance and expression of the novel CD44st via NF-κB in human breast cancer MCF-7 cells.
Fang XJ; Jiang H; Zhu YQ; Zhang LY; Fan QH; Tian Y
Oncol Rep; 2014 Jun; 31(6):2735-42. PubMed ID: 24715151
[TBL] [Abstract][Full Text] [Related]
14. SENP2 suppresses epithelial-mesenchymal transition of bladder cancer cells through deSUMOylation of TGF-βRI.
Tan M; Zhang D; Zhang E; Xu D; Liu Z; Qiu J; Fan Y; Shen B
Mol Carcinog; 2017 Oct; 56(10):2332-2341. PubMed ID: 28574613
[TBL] [Abstract][Full Text] [Related]
15. Dioscin strengthens the efficiency of adriamycin in MCF-7 and MCF-7/ADR cells through autophagy induction: More than just down-regulation of MDR1.
Wang C; Huo X; Wang L; Meng Q; Liu Z; Liu Q; Sun H; Sun P; Peng J; Liu K
Sci Rep; 2016 Jun; 6():28403. PubMed ID: 27329817
[TBL] [Abstract][Full Text] [Related]
16. Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo.
Matsumoto G; Namekawa J; Muta M; Nakamura T; Bando H; Tohyama K; Toi M; Umezawa K
Clin Cancer Res; 2005 Feb; 11(3):1287-93. PubMed ID: 15709200
[TBL] [Abstract][Full Text] [Related]
17. Gain-of-function p53 mutant with 21-bp deletion confers susceptibility to multidrug resistance in MCF-7 cells.
Tsou SH; Hou MH; Hsu LC; Chen TM; Chen YH
Int J Mol Med; 2016 Jan; 37(1):233-42. PubMed ID: 26572087
[TBL] [Abstract][Full Text] [Related]
18. Sensitization of apoptotically-resistant breast carcinoma cells to TNF and TRAIL by inhibition of p38 mitogen-activated protein kinase signaling.
Weldon CB; Parker AP; Patten D; Elliott S; Tang Y; Frigo DE; Dugan CM; Coakley EL; Butler NN; Clayton JL; Alam J; Curiel TJ; Beckman BS; Jaffe BM; Burow ME
Int J Oncol; 2004 Jun; 24(6):1473-80. PubMed ID: 15138590
[TBL] [Abstract][Full Text] [Related]
19. miR-222 induces Adriamycin resistance in breast cancer through PTEN/Akt/p27
Wang DD; Yang SJ; Chen X; Shen HY; Luo LJ; Zhang XH; Zhong SL; Zhao JH; Tang JH
Tumour Biol; 2016 Nov; 37(11):15315-15324. PubMed ID: 27699665
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanism of suppression of MDR1 by puerarin from Pueraria lobata via NF-kappaB pathway and cAMP-responsive element transcriptional activity-dependent up-regulation of AMP-activated protein kinase in breast cancer MCF-7/adr cells.
Hien TT; Kim HG; Han EH; Kang KW; Jeong HG
Mol Nutr Food Res; 2010 Jul; 54(7):918-28. PubMed ID: 20077420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
